View Future GrowthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsQuanta 過去の業績過去 基準チェック /06Quantaは36.6%の年平均成長率で業績を伸ばしているが、Pharmaceuticals業界はgrowingで9.4%毎年増加している。売上は減少しており、年平均63.3%の割合である。主要情報36.63%収益成長率87.15%EPS成長率Pharmaceuticals 業界の成長5.95%収益成長率-63.33%株主資本利益率n/aネット・マージン-1,494.48%前回の決算情報31 Mar 2022最近の業績更新更新なしすべての更新を表示Recent updatesお知らせ • Aug 17Quanta, Inc. announced delayed 10-Q filingOn 08/16/2022, Quanta, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 17Quanta, Inc. announced delayed 10-Q filingOn 05/16/2022, Quanta, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Mar 29Quanta, Inc. announced delayed annual 10-K filingOn 03/28/2022, Quanta, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Aug 14Quanta, Inc. announced delayed 10-Q filingOn 08/13/2021, Quanta, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 12Quanta, Inc. announced delayed 10-Q filingOn 05/11/2021, Quanta, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 02Quanta, Inc. announced delayed annual 10-K filingOn 03/31/2021, Quanta, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Dec 23Quanta, Inc. (OTCPK:QNTA) entered into an agreement to acquire 51% stake in Medolife International, Inc.Quanta, Inc. (OTCPK:QNTA) entered into an agreement to acquire 51% stake in Medolife International, Inc. on December 21, 2020. In exchange, Quanta will issue 9000 shares newly created Series B Convertible Preferred Stock. Arthur G. Mikaelian, Ph.D was appointed as a member of the Board of Directors of Quanta, Inc and was also appointed to serve as the Company’s Chief Executive Officer. The acquisition is subject to customary due diligence by both parties, and to the approval of Quanta, Inc. shareholders.お知らせ • Nov 19Quanta, Inc. Announces Change of CEOThe Directors of Quanta, Inc. announced that pursuant to the Company's Transition to a Holding Company, Phil Sands was previously appointed as a member of the Company's Board of Directors. Mr. Sands also appointed as the Company's Chief Executive Officer, with such appointment as CEO to be effective ten days following the mailing of a Schedule 14F Information Statement to the Company's Shareholders. The appointment of Mr. Sands as CEO, the Company has received and hereby accepts the resignation letter of Eric Rice from all officer positions with the Company, to be effective ten days following the mailing of the Schedule 14F Information Statement to the Company's Shareholders.お知らせ • Nov 14Quanta, Inc. Appoints Phil Sands as Member of the Board of DirectorsOn November 13, 2020, Mr. Phil Sands was appointed as a member of the Board of Directors of Quanta, Inc. Mr. Phil Sands, age 59, brings over 20 plus years of corporate executive experience, business development, project management, investment consultation, and B2B sales experience within Small Business and Corporate America. He has served in diverse companies with positions of Investment Consultant, Business Development Manager, Director of Investor Relations and Principal of small businesses. Mr. Sands has through collaboration worked with investment firms and helped developed strategies for public and private funding offerings, debt debenture offerings, help with Private Placements, balance sheet review and offer investment location consultation, client presentation, coaching, and access to market makers and broker dealers. Has worked with clients from all sectors with diverse back grounds on the OTC markets as well NASDAQ companies. Sectors range from alternative energy, technical, medical, manufacturing and more.お知らせ • Nov 13Quanta, Inc. announced delayed 10-Q filingOn 11/12/2020, Quanta, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 15Quanta, Inc. announced delayed 10-Q filingOn 08/14/2020, Quanta, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.収支内訳Quanta の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:QNTA 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Mar 220-65031 Dec 211-88030 Sep 211-88030 Jun 211-108031 Mar 211-107131 Dec 201-86030 Sep 201-97030 Jun 201-77131 Mar 201-77031 Dec 191-66030 Sep 191-44030 Jun 191-34031 Mar 190-22031 Dec 180-22031 Mar 180-100質の高い収益: QNTAは現在利益が出ていません。利益率の向上: QNTAは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: QNTAの過去 5 年間の前年比収益成長率がプラスであったかどうかを判断するにはデータが不十分です。成長の加速: QNTAの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: QNTAは利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( -4.8% ) と比較することは困難です。株主資本利益率高いROE: QNTAの負債は資産を上回っているため、自己資本利益率を計算することは困難です。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/05/17 14:03終値2023/05/15 00:00収益2022/03/31年間収益2021/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Quanta, Inc. これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Aug 17Quanta, Inc. announced delayed 10-Q filingOn 08/16/2022, Quanta, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 17Quanta, Inc. announced delayed 10-Q filingOn 05/16/2022, Quanta, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Mar 29Quanta, Inc. announced delayed annual 10-K filingOn 03/28/2022, Quanta, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Aug 14Quanta, Inc. announced delayed 10-Q filingOn 08/13/2021, Quanta, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 12Quanta, Inc. announced delayed 10-Q filingOn 05/11/2021, Quanta, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 02Quanta, Inc. announced delayed annual 10-K filingOn 03/31/2021, Quanta, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Dec 23Quanta, Inc. (OTCPK:QNTA) entered into an agreement to acquire 51% stake in Medolife International, Inc.Quanta, Inc. (OTCPK:QNTA) entered into an agreement to acquire 51% stake in Medolife International, Inc. on December 21, 2020. In exchange, Quanta will issue 9000 shares newly created Series B Convertible Preferred Stock. Arthur G. Mikaelian, Ph.D was appointed as a member of the Board of Directors of Quanta, Inc and was also appointed to serve as the Company’s Chief Executive Officer. The acquisition is subject to customary due diligence by both parties, and to the approval of Quanta, Inc. shareholders.
お知らせ • Nov 19Quanta, Inc. Announces Change of CEOThe Directors of Quanta, Inc. announced that pursuant to the Company's Transition to a Holding Company, Phil Sands was previously appointed as a member of the Company's Board of Directors. Mr. Sands also appointed as the Company's Chief Executive Officer, with such appointment as CEO to be effective ten days following the mailing of a Schedule 14F Information Statement to the Company's Shareholders. The appointment of Mr. Sands as CEO, the Company has received and hereby accepts the resignation letter of Eric Rice from all officer positions with the Company, to be effective ten days following the mailing of the Schedule 14F Information Statement to the Company's Shareholders.
お知らせ • Nov 14Quanta, Inc. Appoints Phil Sands as Member of the Board of DirectorsOn November 13, 2020, Mr. Phil Sands was appointed as a member of the Board of Directors of Quanta, Inc. Mr. Phil Sands, age 59, brings over 20 plus years of corporate executive experience, business development, project management, investment consultation, and B2B sales experience within Small Business and Corporate America. He has served in diverse companies with positions of Investment Consultant, Business Development Manager, Director of Investor Relations and Principal of small businesses. Mr. Sands has through collaboration worked with investment firms and helped developed strategies for public and private funding offerings, debt debenture offerings, help with Private Placements, balance sheet review and offer investment location consultation, client presentation, coaching, and access to market makers and broker dealers. Has worked with clients from all sectors with diverse back grounds on the OTC markets as well NASDAQ companies. Sectors range from alternative energy, technical, medical, manufacturing and more.
お知らせ • Nov 13Quanta, Inc. announced delayed 10-Q filingOn 11/12/2020, Quanta, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 15Quanta, Inc. announced delayed 10-Q filingOn 08/14/2020, Quanta, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.